Coronavirus Live Count Map India
remove_red_eye 771 Views
Coronavirus Live Count Map World
#Neurology #Pharmacist #Psychiatry
Coronavirus FAQ PDF
An analysis of all postmarketing reports of deaths and serious adverse events (SAEs) reported with the use of Nuplazid (pimavanserin) by the US FDA has found no new or unexpected safety risks associated with Nuplazid (pimavanserin), which is used to treat the hallucinations and delusions of Parkinson’s disease psychosis. In a statement issued September 20, 2018, the FDA said, “the drug’s benefits outweigh its risks for patients with hallucinations and delusions of Parkinson’s disease psychosis”.